Clinical Oncology Next-Generation Sequencing Market: size was valued at US $ 7.86 Bn.in 2022 and the total revenue is expected to grow at 20.7% through 2022 to 2029, reaching nearly US$ 2.93 Bn.
Clinical Oncology Next-Generation Sequencing Market Overview:
A market analysis on Clinical Oncology Next-Generation Sequencing was released by Maximise Market Research (MMR). Drawing from primary and secondary sources, the research presents a thorough overview of the Clinical Oncology Next-Generation Sequencing market. As an investor’s guide, it offers a thorough study of the market’s size and share in every area and category.
Clinical Oncology Next-Generation Sequencing Market Dynamics:
The market for next-generation sequencing in clinical oncology is anticipated to lead in the next years due to factors such as the rising incidence of cancer and technological advancements in the sector. Additionally, it is anticipated that during the anticipated era, a rise in the preference for NGS over single-gene research would present significant prospects for market expansion.
For detail insights on this market, request for methodology here@ https://www.maximizemarketresearch.com/request-sample/100383
Clinical Oncology Next-Generation Sequencing Market Report Scope and Research Methodology:
The report provides an in-depth analysis of the Clinical Oncology Next-Generation Sequencing Market at the global, regional, and country levels. It also provides a comprehensive analysis of the competitive landscape of the Property Management industry, including the business strategies adopted by the key players. The report includes a list of Property Management key competitors, along with their revenue, production capacity, sales, and global presence. SWOT analysis was used to identify the strengths and weaknesses of the key players in the Property Management industry. Detailed information on the Clinical Oncology Next-Generation Sequencing Market dynamics, including drivers, restraints, opportunities, and challenges, is also provided in the report. The bottom-up approach was used to estimate the global and regional Clinical Oncology Next-Generation Sequencing Market size. Both primary and secondary research methods were used to gather data on market size, market share, regional insights, market dynamics, the performance of key players, and historical data of the industry. The report also includes a detailed value chain analysis, which helps to understand the manufacturing process of Property Management, with information on raw materials, customers, and distributors. Additionally, the report includes PORTER, PESTLE analysis, and market attractiveness, which help to understand the Clinical Oncology Next-Generation Sequencing Market at both macro and micro levels.
Clinical Oncology Next-Generation Sequencing Market Regional Insights:
Geographically, the report is segmented into several key countries, including:
North America: the United States, Canada, and Mexico
Europe: the United Kingdom, Germany, France, Spain, Italy, and the rest of Europe
Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN countries, and the rest of Asia Pacific
South America: Brazil
Middle East and Africa
Clinical Oncology Next-Generation Sequencing Market Segmentation:
by Technology
• Whole Genome Sequencing
• Whole Exome Sequencing
• Targeted Sequencing & Resequencing Centrifuges
With a sales share of more than 72% in 2020, the targeted sequencing and resequencing segment saw tremendous growth based on technology. The cost, time, and amount of data analysed during the sequencing of tumour samples are often reduced by targeted cancer sequencing panels. Furthermore, the therapeutic efficacy of targeted panels is enhanced by their capacity to detect malignant tumours. A 2020 JCO Precision Oncology research found that 64 percent of cancer cases can be treated clinically with NGS panels.
by Workflow
• Pre Sequencing
• Sequencing
• Data Analysis
Sequencing accounted for over 54% of overall revenue, making it the most profitable process category according to process. One of the most important stages of the workflow, sequencing calls for the usage of specialised platforms. The growth of the segment is further supported by an increase in the quantity of cancer sequencing programmes. The primary drivers of the pre-sequencing portion are the attempts of major stakeholders to lower the cost of NGS library planning. It is anticipated that NGS data analysis would become more common. The creation of advanced analytical tools by prominent industry players is driving the growth of this area. More than 2,600 tumour samples from 38 distinct cancer types were sequenced by the Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium.
by Application
• Screening
• Companion Diagnostics
• Other Diagnostics
According to the application, the screening generated the largest revenue share—more than 79%. It is currently believed that NGS-based research is the most efficient way to find genetic alterations in cancer patients that can be used to their advantage as a therapy. Physicians can now analyse many gene variants simultaneously thanks to this technology. Alliances and partnerships among important stakeholders, together with continuous product innovation, are expected to drive the adoption of NGS for companion diagnostics.
by End-User
• Hospitals
• Clinics
• Laboratories
Over the course of the projected period, the laboratories category emerged as the industry leader, accounting for over 65 percent of total sales, according to End User data. It takes a lot of time to set up dynamic workflows in laboratories. Because of this, most specialised labs have already created workflows based on standard operating procedures. Furthermore, thorough guidelines for processes requiring NGS testing have been built as a result of the quick development and distribution of NGS assays for clinical application. Because of this, the majority of FDA-approved evaluations demonstrate the validity of their conclusions through the use of tried-and-true controls, criteria, and performance attributes.
For detail insights on this market, request for methodology here@ https://www.maximizemarketresearch.com/request-sample/100383
Clinical Oncology Next-Generation Sequencing Market Key Players:
• Illumina, Inc.
• QIAGEN
• Thermo Fisher Scientific, Inc.
• F. Hoffman-La Roche Technologies
• Agilent Technologies
• Myriad Genetics
• Foundation Medicine
• Pacific Bioscience
• Oxford Nanopore Technologies Ltd.
• Beijing Genomics Institute (BGI)
• Perkin Elmer, Inc.
• Paradigm Diagnostics
• Caris Life Sciences
• Partek, Inc.
• Eurofins Scientific S.E.
• Bio Rad Laboratories, Inc.
• Other Key Players
For any Queries Linked with the Report, Ask an Analyst@ https://www.maximizemarketresearch.com/market-report/clinical-oncology-next-generation-sequencing-market/100383/
Key Questions answered in the Clinical Oncology Next-Generation Sequencing Market Report are:
- What is the expected Clinical Oncology Next-Generation Sequencing Market size by 2029?
- What will be the CAGR of the Clinical Oncology Next-Generation Sequencing Market during the forecast period?
- What are the Clinical Oncology Next-Generation Sequencing Market segments?
- Which segment held the largest share in the Clinical Oncology Next-Generation Sequencing Market?
- How is the competitive scenario of the Clinical Oncology Next-Generation Sequencing Market?
- Which are the key factors driving the Clinical Oncology Next-Generation Sequencing Market growth?
- What are the key factors restraining the Clinical Oncology Next-Generation Sequencing Market?
- Which region holds the maximum share in the Clinical Oncology Next-Generation Sequencing Market?
- Who are the key players in the Property Management industry?
Key Offerings:
- Market Overview
- Market Share
- Market Size
- Forecast |2023-2029
- Market Dynamics- Growth drivers, Restraints, Investment Opportunities, and key trends
- Market Segmentation- A detailed analysis of each segment and their segments
- Competitive Landscape – Leading key players and other prominent key players.
About Maximize Market Research:
Maximize Market Research is a multifaceted market research and consulting company with professionals from several industries. Some of the industries we cover include medical devices, pharmaceutical manufacturers, science and engineering, electronic components, industrial equipment, technology and communication, cars and automobiles, chemical products and substances, general merchandise, beverages, personal care, and automated systems. To mention a few, we provide market-verified industry estimations, technical trend analysis, crucial market research, strategic advice, competition analysis, production and demand analysis, and client impact studies.
Contact Maximize Market Research:
3rd Floor, Navale IT Park, Phase 2
Pune Banglore Highway, Narhe,
Pune, Maharashtra 411041, India
+91 96071 95908, +91 9607365656
